Send me real-time posts from this site at my email

Why Array Biopharma Rose 22%

Analysts reiterated their buy call on $ARRY stock. The company reported clinical results for its colorectal cancer drug. Life expectancyrose to 8.4 months. Despite the uneven clinical results, markets took the stock ~25% higher. 


Analyst Rating   PT  
3.2 Buy $34 Cantor Fitzgerald
4.5 Buy $32 SunTrust Robinson
4.4 Buy 35 Piper Jaffray
3.4 Buy $25 Cowen & Co.

Watch Arry stock in the coming days.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue